SLDB insider buying and SEC filings, explained
Solid Biosciences Inc. · CIK 1707502
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$19K
Planned sales (10b5-1)
$2.7M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 19, 2026 | Planned (10b5-1) | Gabriel Brooks (Chief Medical Officer) sold 4,374 shares at $5.62 ($25K), marked as a 10b5-1 plan trade. Holdings down 4% to 97,241 shares. | SEC filing Filed Oct 20, 2026, 4:05 PM ET |
| Feb 18, 2026 | Planned (10b5-1) | Alexander Cumbo (CEO and Director) sold 16,644 shares at about $5.82 ($97K), marked as a 10b5-1 plan trade. Holdings down 7% to 235,405 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Jessie Hanrahan (Chief Regulatory Officer) sold 4,134 shares at about $5.82 ($24K), marked as a 10b5-1 plan trade. Holdings down 5% to 74,318 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Ilan Ganot (Director) sold 2,658 shares indirectly (by spouse) at about $5.82 ($15K), marked as a 10b5-1 plan trade. Holdings by spouse down 9% to 27,474 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Paul Herzich (Chief Technology Officer) sold 3,616 shares at about $5.82 ($21K), marked as a 10b5-1 plan trade. Holdings down 5% to 72,638 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | David T Howton (President / COO) sold 7,469 shares at about $5.82 ($43K), marked as a 10b5-1 plan trade. Holdings down 7% to 105,077 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Gabriel Brooks (Chief Medical Officer) sold 0 shares; the filing does not report a price. Holdings up <1% to 89,466 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Kevin Tan (CFO) sold 5,404 shares at about $5.82 ($31K), marked as a 10b5-1 plan trade. Holdings down 5% to 99,422 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | David T Howton (President / COO) sold 18,894 shares at about $6.44 ($122K), marked as a 10b5-1 plan trade. Holdings down 16% to 97,859 shares. | SEC filing Filed Feb 6, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | Alexander Cumbo (CEO and Director) sold 48,913 shares at about $6.44 ($315K), marked as a 10b5-1 plan trade. Holdings down 18% to 222,018 shares. | SEC filing Filed Feb 6, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | Ilan Ganot (Director) sold 7,205 shares indirectly (by spouse) at about $6.44 ($46K), marked as a 10b5-1 plan trade. Holdings by spouse down 22% to 25,271 shares. | SEC filing Filed Feb 6, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | Kevin Tan (CFO) sold 14,783 shares at about $6.44 ($95K), marked as a 10b5-1 plan trade. Holdings down 14% to 94,201 shares. | SEC filing Filed Feb 6, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | Gabriel Brooks (Chief Medical Officer) sold 12,616 shares at about $6.44 ($81K), marked as a 10b5-1 plan trade. Holdings down 13% to 84,092 shares. | SEC filing Filed Feb 6, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | Jessie Hanrahan (Chief Regulatory Officer) sold 12,348 shares at about $6.44 ($80K), marked as a 10b5-1 plan trade. Holdings down 15% to 70,327 shares. | SEC filing Filed Feb 6, 2026 |
| Feb 4, 2026 | Planned (10b5-1) | Paul Herzich (Chief Technology Officer) sold 10,905 shares at about $6.44 ($70K), marked as a 10b5-1 plan trade. Holdings down 14% to 69,067 shares. | SEC filing Filed Feb 6, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Kevin Tan (CFO) sold 26,837 shares at about $6.44 ($173K), marked as a 10b5-1 plan trade. Holdings down 20% to 108,984 shares. | SEC filing Filed Feb 2, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Alexander Cumbo (CEO and Director) sold 80,258 shares at about $6.44 ($517K), marked as a 10b5-1 plan trade. Holdings down 23% to 270,931 shares. | SEC filing Filed Feb 2, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Jessie Hanrahan (Chief Regulatory Officer) sold 26,535 shares at about $6.44 ($171K), marked as a 10b5-1 plan trade. Holdings down 24% to 82,675 shares. | SEC filing Filed Feb 2, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Gabriel Brooks (Chief Medical Officer) sold 28,335 shares at about $6.44 ($182K), marked as a 10b5-1 plan trade. Holdings down 23% to 96,708 shares. | SEC filing Filed Feb 2, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | David T Howton (President / COO) sold 37,771 shares at about $6.44 ($243K), marked as a 10b5-1 plan trade. Holdings down 24% to 116,753 shares. | SEC filing Filed Feb 2, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Paul Herzich (Chief Technology Officer) sold 26,250 shares at about $6.44 ($169K), marked as a 10b5-1 plan trade. Holdings down 25% to 79,972 shares. | SEC filing Filed Feb 2, 2026 |
| Jan 28, 2026 | Planned (10b5-1) | Ilan Ganot (Director) sold 191 shares indirectly (by spouse) at $6.59 ($1K), marked as a 10b5-1 plan trade. Holdings by spouse down 1% to 17,476 shares. | SEC filing Filed Jan 30, 2026 |
| Jan 13, 2026 | Planned (10b5-1) | Kevin Tan (CFO) sold 5,704 shares at $5.27 ($30K), marked as a 10b5-1 plan trade. Holdings down 11% to 46,100 shares. | SEC filing Filed Jan 13, 2026 |
| Jan 5, 2026 | Sale | Ilan Ganot (Director) sold 1,053 shares indirectly (by spouse) at $5.43 ($6K). Holdings by spouse down 6% to 17,278 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 6, 2026 |
| Dec 3, 2025 | Planned (10b5-1) | David T Howton (President / COO) sold 4,932 shares at $5.11 ($25K), marked as a 10b5-1 plan trade. Holdings down 13% to 32,908 shares. | SEC filing Filed Dec 4, 2025 |
| Dec 3, 2025 | Planned (10b5-1) | Alexander Cumbo (CEO and Director) sold 10,808 shares at $5.11 ($55K), marked as a 10b5-1 plan trade. Holdings down 12% to 81,388 shares. | SEC filing Filed Dec 4, 2025 |
| Dec 3, 2025 | Planned (10b5-1) | Jessie Hanrahan (Chief Regulatory Officer) sold 4,483 shares at $5.11 ($23K), marked as a 10b5-1 plan trade. Holdings down 14% to 26,660 shares. | SEC filing Filed Dec 4, 2025 |
| Dec 3, 2025 | Planned (10b5-1) | Paul Herzich (Chief Technology Officer) sold 2,701 shares at $5.11 ($14K), marked as a 10b5-1 plan trade. Holdings down 9% to 26,622 shares. | SEC filing Filed Dec 4, 2025 |
| Nov 10, 2025 | Sale | Ilan Ganot (Director) sold 3,278 shares at about $4.12 ($14K). Holdings down 3% to 95,412 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 13, 2025 |
43 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow SLDB in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.